Tag: Neurodegenerative disease

In September 2024, the U.S. Food and Drug Administration (FDA) approved Aqneursa (levacetylleucine) for the treatment of neurological symptoms associated with Niemann-Pick disease type C (NPC), classifying it as a modified amino acid. This orally administered medication addresses the progressive neurological decline seen in this rare genetic disorder.

Recent studies have identified **Cypin** as a key protein involved in regulating synaptic connections in the brain, a breakthrough with potential implications for treating neurodegenerative diseases. However, confusion often arises with "Cypin Syrup," a separate medication containing the active antihistamine, cyproheptadine.

In pre-clinical studies, a single dose of trodusquemine led to a 20% reduction in body weight in mice on a high-fat diet [1.3.9]. This article explores the question: What are the benefits of trodusquemine, an investigational drug with a unique mechanism of action?